Venn Life Sciences, Chris Bailey on Dunelm, Dixons Carphone and BT plus Glen Goodman on Crypto

Justin Waite
Vox Markets Podcast with Justin Waite
12:21, 20th June 2019

Vox Media Player

 

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Venn Life Sciences, Chris Bailey on Dunelm, Dixons Carphone and BT plus Glen Goodman on Crypto

Cathal Friel, CEO of Venn Life Sciences (VENN) FOLLOW discusses how their fundraise is going to be used to transform Venn and acquire Open Ophan to target the fragmented orphan drug services market in Europe.

Open Orphan was incorporated in the Republic of Ireland on 18 July 2017 with a strategy and product offering to develop a market leading services platform for pharmaceutical and biotechnology companies seeking to commercialise their products across Europe with a particular focus on drugs treating rare diseases. It has raised over €3 million from investors to build a platform that facilitates obtaining European Medical Agency approval, and/or relevant local approval, and pan-European reimbursement, for launch and commercialisation of orphan and other rare disease drugs.


Chris Bailey founder of Financial Orbit covers:

Dunelm (DNLM) FOLLOW

Dixons Carphone (DC.) FOLLOW

BT (BT.A) FOLLOW

(Interview starts at 11 minutes 30 seconds)


Glen Goodman, former ITV News Business correspondent and now author of, "The Crypto Trader", provides some insight into the world of crypto currency trading.

(Interview starts at 26 minutes 39 seconds)  

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
Login or register to post comments

Recent Articles
Watchlist